Biocon subsidiary Biocon Biologics has received approval from the Drugs Controller General of India (DCGI) for the use of extracorporeal blood purification (EBP) device CytoSorb in the treatment of COVID-19 patients. The license will be effective until control of the COVID-19 outbreak in the country.

What this means:
With the regulatory nod, Biocon Biologics will be able to treat COVID-19 patients, aged 18 and above, who have been admitted to the intensive care units (ICU) with confirmed or imminent respiratory failure. CytoSorb is an in-licensed unique device that reduces cytokine storm in critically ill patients and was introduced by Biocon in India in 2013. The approval will provide an impetus to the Company in their role in aiding Corona Virus Treatment efforts.

Latest

At the recent United Nations Climate Change Conference at Glasgow (COP26), India pledged to achieve net-zero carbon emissions by 2070. The Centre has committed to installing a non-fossil fuel electricity generation capacity of 500 gigawatts (GW) and sourcing 50% of India’s energy requirement from renewable sources by 2030. The government also aims to reduce 1 […]

Advertisement